International

Russia Develops Another Covid-19 Vaccine, Deputy PM Participates In Trial

Putin

Russia Scientists who developed the vaccine in an interaction with the media said that it produces enough antibodies to protect the person from the corona virus.

 

Moscow| At a time when two ongoing trials for Covid-19 vaccine have been halted due to volunteers falling sick, Russia has claimed that it has developed another vaccine for Covid-19. Russia has approved its second corona vaccine after the initial trial. During a meeting with government officials, Russian President Vladimir Putin announced on Wednesday that the country has approved the second corona virus vaccine ‘EpiVacCorona’ after the initial trial. Earlier, Russia has created Sputnik-5 vaccine against Corona.

Russian President Vladimir Putin said that now the country needs to ramp up the production of the first and second vaccine. This vaccine has been created by the Vector Institute in Siberia, which is peptide-based and two doses of this vaccine must be administered to prevent corona. It has been tested on around 100 volunteers.

According to news agency PTI, it has been tried for two months and now approved after completion of its initial study two weeks ago. According to Russia, the initial trials of this vaccine have been successful and that the volunteers who participated in this trial were aged between 18 and 60 years.

However, scientists have not yet published the results of the study. Scientists who developed the vaccine in an interaction with the media said that it produces enough antibodies to protect the person from the corona virus and the immunity it creates can last up to six months.

Russia’s Deputy Prime Minister Tatyana Golikova has administered this vaccine. She had earlier said that she also participated in the initial trial as a volunteer. Golikova has said that 40,000 volunteers across the country will be selected for the next phase trial of Corona’s ‘EpiVacCorona’ vaccine. However, it is unclear whether the vaccine will be offered for wider use while trials are still ongoing.

Dear Readers,
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.

Related posts